Maggie L. Shaw

On the final day of the 2025 Conference on Retroviruses and Opportunistic Infections, Katrina Ortblad, ScD, MPH, implementation scientist and assistant professor, Cancer Prevention Program, Fred Hutch Cancer Center, presented “Leveraging Private-Sector Pharmacies to Expand the Reach of Biomedical HIV […]

“I’ve done a lot of couples-based interventions to focus on improving relationship quality and things like communication skills,” noted Lynae Darbes, PhD, professor, School of Nursing, University of Michigan, and a clinical psychologist by training, “in the thinking that this

The open-label MK-8591A-051 (NCT05631093) trial and the double-blind MK-8591A-052 (NCT05630755) trial, both from Merck, are evaluating the efficacy and safety of 100-mg doravirine (DOR) and 0.25-mg islatravir (ISL) as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1.

In this discussion with Priscilla Tsondai, MD, MPH, technical lead for the pediatric and adolescent program at the International AIDS Society through the Collaborative Initiative for Paediatric HIV Education and Research, she discusses her work focused on improving outcomes for

As a woman living with HIV and a nurse by trade, Bridgette J. Picou, LVN, ACLPN’s advocacy work in the HIV space is a work of hearts. In her role as stakeholder liaison for The Well Project in Brooklyn, New

People living with HIV face challenges connected to managing long COVID that populations not living with HIV may not, including overlapping symptomatology and reduced rates of both recognition that they have this comorbidity and it being diagnosed. To reduce these

Mia Moore, PhD, staff scientist and mathematical modeler at Fred Hutch Cancer Center, is first author of the poster, “Estimating Population Immunity and Impact of COVID-19 Vaccination in Washington and Oregon,” presented at the 2025 Conference on Retroviruses and Opportunistic

Modified vaccinia Ankara–vectored vaccines using the Mosaic-1 and Mosaic-2 immunogens (collectively HIVconsvX) to target the same 6 HIV regions are safe to use and elicited an immune response in people living with HIV and currently taking antiretroviral therapy (ART), according

Speech and language pathology evaluation are not occurring at sufficient levels among individuals with myasthenia gravis, according to new research published in OTO Open.1 Investigators uncovered that despite higher rates of dysarthria (inability to speak clearly), dysphonia (hoarse voice), dysphagia

In part 2 of this interview with Frederick L. Locke, MD, lead investigator on the phase 1 ALPHA (NCT03939026) and ALPHA2 (NCT04416984) trials of allogeneic chimeric antigen receptor T-cell therapy (CAR T) in relapsed/refractory large B-cell lymphoma (LBCL), explains why